RON AFSHARI ADELMAN, MD
Medical Practice in New Haven, CT
License number
Connecticut 039731
Category
Medical Practice
Type
Ophthalmology
Address
Address
800 Howard Ave Yale BLDG PHYSICIANS, New Haven, CT 06519
Phone
(203) 785-2140
(203) 785-6414 (Fax)
(203) 785-7998
(203) 785-6414 (Fax)
(203) 785-7998
Personal information
See more information about RON AFSHARI ADELMAN at radaris.comName
Address
Phone
52 Quarry Ln, Hamden, CT 06518
52 Quarry Ln, Hamden, CT 06518
330 Cedar St, New Haven, CT 06510
40 Temple St, New Haven, CT 06510
Professional information
See more information about RON AFSHARI ADELMAN at trustoria.com
Dr. Ron A Adelman, New Haven CT - MD (Doctor of Medicine)
Dr. Ron A Adelman, New Haven CT - MD (Doctor of Medicine)
Specialties:
Ophthalmology
Address:
Yale Eye Center
40 Temple St SUITE 3A, New Haven 06510
(203) 785-2020 (Phone)
40 Temple St SUITE 3D, New Haven 06510
(203) 785-2020 (Phone)
40 Temple St SUITE 3A, New Haven 06510
(203) 785-2020 (Phone)
40 Temple St SUITE 3D, New Haven 06510
(203) 785-2020 (Phone)
Certifications:
Ophthalmology, 2000
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Yale Eye Center
40 Temple St SUITE 3A, New Haven 06510
40 Temple St SUITE 3D, New Haven 06510
Yale - New Haven Hospital
20 York St, New Haven 06510
40 Temple St SUITE 3A, New Haven 06510
40 Temple St SUITE 3D, New Haven 06510
Yale - New Haven Hospital
20 York St, New Haven 06510
Education:
Medical School
University Of Tehran Faculty Of Med
Graduated: 1987
Harvard University
University Of Tehran Faculty Of Med
Graduated: 1987
Harvard University
Ron Afshari Adelman, New Haven CT
Ron Afshari Adelman, New Haven CT
Specialties:
Ophthalmologist
Address:
40 Temple St, New Haven, CT 06510
Education:
Doctor of Medicine
Board certifications:
American Board of Ophthalmology Certification in Ophthalmology
Factor Vii Conjugates For Selectively Treating Neovascularization Disorders
Factor Vii Conjugates For Selectively Treating Neovascularization Disorders
US Patent:
2006005, Mar 9, 2006
Filed:
Aug 15, 2005
Appl. No.:
11/203730
Inventors:
Alan Garen - New Haven CT, US
Ron Adelman - Hamden CT, US
Zhiwei Hu - New Haven CT, US
Ron Adelman - Hamden CT, US
Zhiwei Hu - New Haven CT, US
International Classification:
A61K 38/41
US Classification:
514006000, 514012000, 530383000, 530409000
Abstract:
Methods and compositions are provided for the treatment of diseases such as exudative macular degeneration, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, retinal neovascularization, iris neovascularization, corneal neovascularization, ocular tumors, and other disorders of the eye, cancer, and inflammatory disorders. The method involves administering a conjugate, referred to as fVIIPD, containing a photosensitizer and a targeting molecule such as factor VII (“fVII”), fVIIa, or modified fVII, which binds with high affinity and specificity to tissue factor (TF). TF is more highly expressed, abnormally expressed or specifically expressed on endothelial cells lining the luminal surface of pathological neovasculature, than on normal vasculature, thus providing a specific and accessible therapeutic target. Following administration of fVIIPD, the compound specifically binds to the pathological neovasculature of the eye by interaction of the targeting molecule with TF expressed by endothelial cells within abnormal blood vessels. The photosensitizer may then be activated with a non-thermal laser light for selective destruction of abnormal vasculature.